Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T16596 Target Info
Target Name PIM-3 protein kinase (PIM3)
Synonyms Serine/threonine-protein kinase pim-3
Target Type Patented-recorded Target
Gene Name PIM3
Biochemical Class Kinase
UniProt ID
PIM3_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US9682991
Title Tricyclic compounds for use as kinase inhibitors
Abstract There is provided compounds of formula (I), wherein R1, R2, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).
Applicant(s) FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Representative Drug(s) D0EH6G Drug Info IC50 < 100nM Click to Show More [1]
2 D00HBJ Drug Info IC50 = 550 nM [1]
3 D0V5JW Drug Info IC50 = 550 nM [1]
Patent ID US9682991
Title Tricyclic compounds for use as kinase inhibitors
Abstract There is provided compounds of formula (I), wherein R1, R2, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).
Applicant(s) FUNDACI&#211;N CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Representative Drug(s) D0EH6G Drug Info IC50 < 100nM Click to Show More [1]
2 D00HBJ Drug Info IC50 = 550 nM [1]
3 D0V5JW Drug Info IC50 = 550 nM [1]
Patent ID US9682991
Title Tricyclic compounds for use as kinase inhibitors
Abstract There is provided compounds of formula (I), wherein R1, R2, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).
Applicant(s) FUNDACI&#211;N CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Representative Drug(s) D0EH6G Drug Info IC50 < 100nM Click to Show More [1]
2 D00HBJ Drug Info IC50 = 550 nM [1]
3 D0V5JW Drug Info IC50 = 550 nM [1]
Patent ID US9580418
Title Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
Abstract The present disclosure describes bicyclic aromatic carboxamide derivatives, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
Applicant(s) Incyte Corporation
Representative Drug(s) D0QU7N Drug Info IC50 < 10nM Click to Show More [2]
2 D05ZQI Drug Info IC50 < 10nM [2]
Patent ID US9580418
Title Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
Abstract The present disclosure describes bicyclic aromatic carboxamide derivatives, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
Applicant(s) Incyte Corporation
Representative Drug(s) D0QU7N Drug Info IC50 < 10nM Click to Show More [2]
2 D05ZQI Drug Info IC50 < 10nM [2]
Patent ID US9573943
Title Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
Abstract Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Applicant(s) Genentech, Inc.
Representative Drug(s) D0D0WQ Drug Info N.A. [3]
Patent ID US9434725
Title 5-azaindazole compounds and methods of use
Abstract 5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Applicant(s) F. HOFFMANN-LA ROCHE AG
Representative Drug(s) D07SHE Drug Info N.A. Click to Show More [4]
2 D0JL8G Drug Info N.A. [4]
3 D0ZY3D Drug Info N.A. [4]
Patent ID US9434725
Title 5-azaindazole compounds and methods of use
Abstract 5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Applicant(s) F. HOFFMANN-LA ROCHE AG
Representative Drug(s) D07SHE Drug Info N.A. Click to Show More [4]
2 D0JL8G Drug Info N.A. [4]
3 D0ZY3D Drug Info N.A. [4]
Patent ID US9434725
Title 5-azaindazole compounds and methods of use
Abstract 5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Applicant(s) F. HOFFMANN-LA ROCHE AG
Representative Drug(s) D07SHE Drug Info N.A. Click to Show More [4]
2 D0JL8G Drug Info N.A. [4]
3 D0ZY3D Drug Info N.A. [4]
Patent ID US9321756
Title Azole compounds as PIM inhibitors
Abstract The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
Applicant(s) AMGEN INC.
Representative Drug(s) D06OKX Drug Info IC50 = 1.988 nM Click to Show More [5]
2 D04VSB Drug Info IC50 = 4.383 nM [5]
3 D08JUU Drug Info IC50 = 4.579 nM [5]
Patent ID US9321756
Title Azole compounds as PIM inhibitors
Abstract The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
Applicant(s) AMGEN INC.
Representative Drug(s) D06OKX Drug Info IC50 = 1.988 nM Click to Show More [5]
2 D04VSB Drug Info IC50 = 4.383 nM [5]
3 D08JUU Drug Info IC50 = 4.579 nM [5]
Patent ID US9321756
Title Azole compounds as PIM inhibitors
Abstract The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
Applicant(s) AMGEN INC.
Representative Drug(s) D06OKX Drug Info IC50 = 1.988 nM Click to Show More [5]
2 D04VSB Drug Info IC50 = 4.383 nM [5]
3 D08JUU Drug Info IC50 = 4.579 nM [5]
Patent ID US8987457
Title Ring-substituted N-pyridinyl amides as kinase inhibitors
Abstract The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
Applicant(s) Novartis AG
Representative Drug(s) D0WU1C Drug Info IC50 = 2.07 nM Click to Show More [6]
2 D0NX6B Drug Info IC50 = 3.05 nM [6]
3 D0LK3O Drug Info IC50 = 3.1 nM [6]
Patent ID US8987457
Title Ring-substituted N-pyridinyl amides as kinase inhibitors
Abstract The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
Applicant(s) Novartis AG
Representative Drug(s) D0WU1C Drug Info IC50 = 2.07 nM Click to Show More [6]
2 D0NX6B Drug Info IC50 = 3.05 nM [6]
3 D0LK3O Drug Info IC50 = 3.1 nM [6]
Patent ID US8987457
Title Ring-substituted N-pyridinyl amides as kinase inhibitors
Abstract The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
Applicant(s) Novartis AG
Representative Drug(s) D0WU1C Drug Info IC50 = 2.07 nM Click to Show More [6]
2 D0NX6B Drug Info IC50 = 3.05 nM [6]
3 D0LK3O Drug Info IC50 = 3.1 nM [6]
Patent ID US8889696
Title Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
Abstract Compounds useful as antiproliferative agents according to Formula (I), wherein n, A, R1, R2, and Ar1 are as defined herein, and salts thereof; antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.
Applicant(s) Temple University&#8212;Of The Commonwealth System Of Higher Education
Representative Drug(s) D04JJM Drug Info IC50 = 0.57 nM [7]
Patent ID US8889696
Title Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
Abstract Compounds useful as antiproliferative agents according to Formula (I), wherein n, A, R1, R2, and Ar1 are as defined herein, and salts thereof; antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.
Applicant(s) Temple University&#8212;Of The Commonwealth System Of Higher Education
Representative Drug(s) D04JJM Drug Info IC50 = 0.57 nM [7]
Patent ID US8829193
Title PIM kinase inhibitors and methods of their use
Abstract The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0P9UF Drug Info IC50 = 2 nM Click to Show More [8]
2 D0ZC0E Drug Info IC50 = 4 nM [8]
3 D04MCF Drug Info IC50 = 5 nM [8]
Patent ID US8829193
Title PIM kinase inhibitors and methods of their use
Abstract The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0P9UF Drug Info IC50 = 2 nM Click to Show More [8]
2 D0ZC0E Drug Info IC50 = 4 nM [8]
3 D04MCF Drug Info IC50 = 5 nM [8]
Patent ID US8829193
Title PIM kinase inhibitors and methods of their use
Abstract The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0P9UF Drug Info IC50 = 2 nM Click to Show More [8]
2 D0ZC0E Drug Info IC50 = 4 nM [8]
3 D04MCF Drug Info IC50 = 5 nM [8]
Patent ID US8759338
Title Heterocyclic kinase inhibitors
Abstract New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0GV1S Drug Info IC50 = 18 nM Click to Show More [9]
2 D0XJ2J Drug Info IC50 = 78 nM [9]
3 D0P4NQ Drug Info IC50 = 3900 nM [9]
Patent ID US8759338
Title Heterocyclic kinase inhibitors
Abstract New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0GV1S Drug Info IC50 = 18 nM Click to Show More [9]
2 D0XJ2J Drug Info IC50 = 78 nM [9]
3 D0P4NQ Drug Info IC50 = 3900 nM [9]
Patent ID US8759338
Title Heterocyclic kinase inhibitors
Abstract New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0GV1S Drug Info IC50 = 18 nM Click to Show More [9]
2 D0XJ2J Drug Info IC50 = 78 nM [9]
3 D0P4NQ Drug Info IC50 = 3900 nM [9]
Patent ID US8669361
Title Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
Abstract Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Applicant(s) F. Hoffmann-La Roche AG
Representative Drug(s) D0WH9N Drug Info N.A. Click to Show More [10]
2 D0I0CN Drug Info N.A. [10]
3 D0DT0E Drug Info N.A. [10]
Patent ID US8669361
Title Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
Abstract Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Applicant(s) F. Hoffmann-La Roche AG
Representative Drug(s) D0WH9N Drug Info N.A. Click to Show More [10]
2 D0I0CN Drug Info N.A. [10]
3 D0DT0E Drug Info N.A. [10]
Patent ID US8669361
Title Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
Abstract Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Applicant(s) F. Hoffmann-La Roche AG
Representative Drug(s) D0WH9N Drug Info N.A. Click to Show More [10]
2 D0I0CN Drug Info N.A. [10]
3 D0DT0E Drug Info N.A. [10]
Patent ID US8592455
Title Kinase inhibitors and methods of their use
Abstract New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0J6HN Drug Info IC50 = 1 nM Click to Show More [11]
2 D0OS2I Drug Info IC50 = 1 nM [11]
3 D0X0BB Drug Info IC50 = 12 nM [11]
Patent ID US8592455
Title Kinase inhibitors and methods of their use
Abstract New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0J6HN Drug Info IC50 = 1 nM Click to Show More [11]
2 D0OS2I Drug Info IC50 = 1 nM [11]
3 D0X0BB Drug Info IC50 = 12 nM [11]
Patent ID US8592455
Title Kinase inhibitors and methods of their use
Abstract New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
Applicant(s) Novartis AG
Representative Drug(s) D0J6HN Drug Info IC50 = 1 nM Click to Show More [11]
2 D0OS2I Drug Info IC50 = 1 nM [11]
3 D0X0BB Drug Info IC50 = 12 nM [11]
Patent ID US8481586
Title Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors
Abstract The invention relates to pyrrolo[2,3-a]carbazole derivatives, to a method for preparing the same, and to the use thereof as PIM kinase inhibitors. The invention can particularly be used in the pharmaceutical field.
Applicant(s) Centre National de la Recherche Scientifique; Universite Blaise Pascal-Clermont-Ferrand II
Representative Drug(s) D0M0TH Drug Info IC50 = 200 nM Click to Show More [12]
2 D0NE0N Drug Info IC50 = 210 nM [12]
3 D06TGF Drug Info IC50 = 440 nM [12]
Patent ID US8481586
Title Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors
Abstract The invention relates to pyrrolo[2,3-a]carbazole derivatives, to a method for preparing the same, and to the use thereof as PIM kinase inhibitors. The invention can particularly be used in the pharmaceutical field.
Applicant(s) Centre National de la Recherche Scientifique; Universite Blaise Pascal-Clermont-Ferrand II
Representative Drug(s) D0M0TH Drug Info IC50 = 200 nM Click to Show More [12]
2 D0NE0N Drug Info IC50 = 210 nM [12]
3 D06TGF Drug Info IC50 = 440 nM [12]
Patent ID US8481586
Title Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors
Abstract The invention relates to pyrrolo[2,3-a]carbazole derivatives, to a method for preparing the same, and to the use thereof as PIM kinase inhibitors. The invention can particularly be used in the pharmaceutical field.
Applicant(s) Centre National de la Recherche Scientifique; Universite Blaise Pascal-Clermont-Ferrand II
Representative Drug(s) D0M0TH Drug Info IC50 = 200 nM Click to Show More [12]
2 D0NE0N Drug Info IC50 = 210 nM [12]
3 D06TGF Drug Info IC50 = 440 nM [12]
References  Top
REF 1 Tricyclic compounds for use as kinase inhibitors. US9682991.
REF 2 Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors. US9580418.
REF 3 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US9573943.
REF 4 5-azaindazole compounds and methods of use. US9434725.
REF 5 Azole compounds as PIM inhibitors. US9321756.
REF 6 Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457.
REF 7 Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696.
REF 8 PIM kinase inhibitors and methods of their use. US8829193.
REF 9 Heterocyclic kinase inhibitors. US8759338.
REF 10 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361.
REF 11 Kinase inhibitors and methods of their use. US8592455.
REF 12 Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.